Amin Kamel

Amin joined Regulus in 2022 and is vice president, of drug metabolism and pharmacokinetics. Prior to joining Regulus, he was the scientific director of Takeda, drug metabolism and pharmacokinetics, where he was responsible for project management, and operations, and served as a scientific advisor. Prior to Takeda, he was a principal investigator at Biogen, where he led project management and provided scientific expertise and support for small molecule drug discovery and early development. Previously, he worked as a research investigator for Novartis Institutes for BioMedical Research, and, prior to that, worked for a number of years as a research scientist at Pfizer Global Research and Development. Amin holds a Ph.D. in chemistry from the University of Rhode Island in collaboration with the University of Delaware.